RemeOs is an MRI-compatible, absorbable hybrid composite and is designed for cervical spinal fusion, the company said in an Oct. 4 news release.
The company’s financial targets were also upgraded in light of the decision to accelerate RemeOs development. Bioretec increased its net sales forecast to more than $71 million by the end of 2028 and expects to see positive operational cash flow by the end of 2027 instead of 2026.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
